Development of next-generation gene therapy and intracellular immunotherapy for Alzheimer's disease
| Project/Area Number |
16K15483
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Oita University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MURAMATSU Shinichi 自治医科大学, 医学部, 教授 (10239543)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | Aβオリゴマー / 遺伝子治療 / AAV / 抗体 / 認知症 |
|---|
| Outline of Final Research Achievements |
Synaptotoxic Aβ Oligomers represent a molecular basis of memory impairment in Alzheimer's dementia (AD), which is considered as a therapeutic target. A modified Adeno associated virus (AAV) vector selectively reaching neurons after intravenous injection allow us to develop low-molecular weight antibodies selectively targeting the intracellular Aβ Oligomers. In spite of our extensive efforts, we failed to obtain the enough amounts of antibodies, owing to unknown lower expression of antibodies from plasmid vector transfected into the mammalian cells. In the future, anyhow, it is necessary to make it work for their acquisition to propose and establish a new therapeutic concept.
|
Report
(3 results)
Research Products
(14 results)
